Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Featured trial
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

  • 208 views
  • 08 Nov, 2020
  • 1 location
RA-PRO PRAGMATIC TRIAL (RA-PROPR)

medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in

tocilizumab
hydroxychloroquine
tofacitinib
abatacept
methotrexate
  • 0 views
  • 28 Jun, 2022
  • 1 location
Tocilizumab in Children With ACP

dose of tocilizumab before they have SOC surgery of their tumor. The objective of this phase is to see if drug reaches the tumor. If phase 0 is favorable and shows that drug is penetrating the tumor

  • 0 views
  • 27 May, 2022
  • 1 location
Tocilizumab in Active Moderate-severe Graves' Orbitopathy

To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and reactivation of disease (Primary Objective) Effect of therapy on disease progression, improvement of QoL, the …

  • 1 views
  • 16 May, 2021
  • 4 locations
TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients (INTERCEPT)

This multi-center study is an investigator-driven randomized controlled parallel group open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody tocilizumab

  • 0 views
  • 22 Mar, 2022
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade. Hence, adding

  • 0 views
  • 10 Dec, 2021
  • 1 location
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

This is a prospective study to investigate the treatment response of Tocilizumab on patients with idiopathic retroperitoneal fibrosisIRPF. Methods: All the patients fulfilling diagnostic

  • 1 views
  • 28 Mar, 2021
  • 1 location
IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout (REX-6)

will be randomized to infusion placebo or tocilizumab (IL-6 receptor antibody) combined with a 2-hour exercise bout. Stable isotope tracers will be infused to determine substrate kinetics. Indirect

Accepts healthy volunteers
  • 0 views
  • 18 May, 2022
  • 1 location
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis (ULTRA)

, abatacept and tocilizumab have been shown to be effective during GCA. However, the therapeutic effect of the first two is modest. As for tocilizumab, its use has many limitations: suspensive effect, many

  • 0 views
  • 29 May, 2022
  • 1 location
Acute Response to Exercise in Patients With Rheumatoid Arthritis

controls will be recruited for an acute session of exercise. RA patients will be divided into 2 groups, according to the pharmacological treatment (tocilizumab or anti-TNF). The acute responses of insulin

edema
tumour necrosis
tumor necrosis factor
tocilizumab
  • 0 views
  • 04 Sep, 2021
  • 1 location